Loading viewer...
investor_presentation
Format: PDF investor_presentation
C O R P O R AT E P R E S E N TAT I O N S E P T E M B E R 2 0 2 1
C O R P O R AT E P R E S E N TAT I O N
S E P T E M B E R 2 0 2 1Broad Oncology Pipeline Designed to Improve Patient Outcomes
Zentalis Pharmaceuticals, Inc.(“we,” “us,” “our,” “Zentalis” orthe“Company”) cautions that this presentation (including oral commentary that accompanies this presentation) contains forward -looking
statements within themeaning ofthePrivate Securities Litigation Reform Actof1995 .Allstatements contained inthis presentation that donotrelate tomatters ofhistorical fact should beconsidered
forward -looking statements, including without limitation statements regarding our future financial orbusiness performance, plans, prospects, trends orstrategies, objectives ofmanagement,
competition and other financial and business matters, thepotential, safety, efficacy, and regulatory and clinical progress ofour current and prospective product candidates, plans and timing forthe
initiation ofand release ofdata from ourclinical trials and ourability tomeet other keymilestones, planned preclinical activities, ourcurrent and prospective collaborations, theestimated size ofthe
market forourproduct candidates, and thetiming and success ofourdevelopment and commercialization ofouranticipated product candidates and themarket acceptance thereof areforward -looking
statements, aswell asstatements that include thewords “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate” and similar statements ofafuture or
forward -looking nature .These statements areneither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results,
performance orachievements tobematerially different from anyfuture results, performance orachievements expressed orimplied bytheforward -looking statements, including, butnotlimited to,the
following :theoutbreak ofthenovel coronavirus disease, COVID -19,hasadversely impacted and may continue toadversely impact ourbusiness, including ourpreclinical studies and clinical trials ;our
limited operating history, which may make itdifficult toevaluate ourcurrent business and predict ourfuture success and viability ;wehave and expect tocontinue toincur significant losses ;ourneed for
additional funding, which may notbeavailable ;oursubstantial dependence onthesuccess ofourlead product candidate ;failure toidentify additional product candidates and develop orcommercialize
marketable products ;theearly stage ofour development efforts ;potential unforeseen events during clinical trials could cause delays orother adverse consequences ;risks relating totheregulatory
approval process orongoing regulatory obligations ;failure toobtain U.S.orinternational marketing approval ;ourproduct candidates may cause serious adverse side effects ;interim, initial, “topline”,
Preview truncated — download the full document for the complete content.
investor_presentation
46 Pages
investor_presentation
32 Pages
PennyMac Financial Services, Inc.
Phibro Animal Health Investor Presentation — May 2022
investor_presentationinvestor_presentation
11 Pages
Phibro Animal Health Corporation